

FVE/FECAVA policy recommendations

Firstly, **it is crucial to monitor FIP prevalence** at both national and European levels, particularly in countries experiencing an increase in cases. By closely tracking the spread of the disease, we can better understand its impact and implement timely interventions.

Secondly, FVE and FECAVA strongly advocate for **increased research efforts** to develop effective vaccines against FIP.

Lastly, we urge policymakers to **provide EU veterinarians with a legal option to treat FIP** - affected cats e.g., allowing them to use either Remdesivir or GS-441524. It is essential that owners no longer feel compelled to turn to the illegal market in their desperate search for life-saving treatments for their beloved cats.

Remdesivir

The nucleoside analogue Remdesivir (also known as Veklury), authorized by EMA for COVID-19 treatment, offers optimistic results in FIP research groups.

In many countries, remdesivir sales are restricted to human hospital pharmacies.



In some European countries the drug's use is permitted under the cascade but acquiring it is difficult, making it available legally but not practically.

Outside the EU

United Kingdom:

- GS-441524 - Legally available in tablet form and oral suspension for example by [BOVA](#) and [Summit](#). Some EU countries allow the import of extemporaneous products from the UK.
- Remdesivir - No supply problems, but its use is restricted to referral practice.

United States:

Compounded GS-441524 is available by veterinary prescription for individual patients and for veterinary office use in permitted states. 50 mg tablets can be sold to hospitals for office use.

Canada:


Canadian [Trutina Pharmacy](#) is producing GS-441524 legally, with proper pharmaceutical grade drug and proper quality control, in collaboration with [BOVA](#) (UK). This allows to use the drug without the restrictions in place for EDR obtained drugs, as previously with Canada's [Veterinary Drugs Directorate \(VDD\)](#) legal import of compounded UK versions.



Federation
of Veterinarians
of Europe



**Feline
Infectious
Peritonitis
(FIP)
Treatment
Challenges
and
Opportunities**



INTRODUCTION



Feline Infectious Peritonitis (FIP) is caused by a mutation of the commonly seen feline coronavirus (FCoV), presenting a grim prognosis for affected cats.



The real prevalence is largely unknown, with 0.3% to 1.4% of feline deaths being potentially attributed to FIP, but likely to be underestimated.



Groundbreaking research allowed the development of new treatment options which allow successful treatment of this once-lethal condition.




The treatment is expensive and lasts generally 12 weeks, but has shown rates of 84% recovery when the disease is treated early.



However, most countries have no legal option for the treatment of FIP, except in clinical trials like in Germany, Switzerland, and the Netherlands. This poses a massive dilemma for veterinarians trying to fulfil their professional responsibility.

GS-441524

GS-44152 is a nucleoside analogue and the breakdown product of Remdesivir. It was shown to be remarkably safe and can be given orally in a treatment plan along with Remdesivir, though an injectable version is available too.



GS-44152 is patented by Gilead Sciences, a company in the US, but not marketed.

Its unavailability in other countries has led to a flourishing black market for the drug, raising concerns about its purity and safety.



Certain manufacturers such as Delpech pharmacy (FR) and FrancePrep provide extemporaneous products containing GS-441524 in tablet form, oral suspension or paste.



Research suggests that treatment duration could be halved to 42 days.



Currently, no pharmaceutical company has attempted to obtain authorisation for a GS-441542 product.

ACTIONS

- FVE and FECAVA have gathered data from several EU and non-EU countries on FIP treatment availability
- FVE and FECAVA have proactively been advocating for the release of a small quantity of Veklury to veterinarians, in a joint letter to the Heads of Medicines Agency.
- FVE and FECAVA held a very successful webinar to raise awareness of the different antiviral FIP treatments, such as remdesivir and GS-441524

FVE's actions in the collective mission to address the health and ethical issue surrounding the FIP treatment have contributed to the current achievements of a wider panorama where FIP can be treated legally.

If you want to learn more about possible FIP treatments or if in your country GS-441524 treatment or import is still unavailable, contact us at info@fve.org.